UCB is a global biopharma focused on severe diseases in two therapeutic areas: central nervous system and immunology operations.
The company is listed on the Euronext Brussels Stock Exchange and has its headquarters in Brussels, Belgium. It employs more than 8,500 people in more than 40 countries.
Financial Data
-
31st Dec 18 Source: CRO
- €36.9 million turnover
-
€25.8 million
profit - 1 employees
-
31st Dec 17 Source: CRO
- €163 million turnover
-
€12.2 million
profit - 1 employees
- 10 more years available »
Ranking
By Turnover
(€36.9 million)- 755th in Top Companies
- 88th in Health
- 75th in Pharma
By Employees
(1)- 986th in Top Companies
- 94th in Health
- 81st in Pharma
-
- 1
- €36.9 million
Employees
- Steve Turley CEO/Managing Director
Latest News
- 3:53pm US removes stumbling block to global deal on digital tax
- 3:16pm Government has no plans to create new employment status for gig workers
- 2:59pm Protego to create 60 new jobs after forming partnership with Repay
- 1:53pm EU likely to approve J&J vaccine in early March
- 12:51pm Household deposits reach yet another historic high